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Introduction
Gene therapy could be useful for congenital and acquired lung diseases that are characterized by chronic airway inflammation and alveolitis/fibrosis, as in cystic fibrosis (CF), 1 surfactant deficiency states, 2 after ionizing irradiation for cancer treatment, 3 or when lung parenchyma destruction ensues, such as in alpha 1 -antitrypsin deficiency. 4 However, many factors can impede the gene transfer process particularly in injured respiratory tracts when a direct delivery is attempted. For example, in CF the lung pathology is characterized by thick dehydrated mucus production. In the other diseases, other barriers such as alveolar accumulation of proteins and lipids or uninhibited neutrophil elastase are present.
Cationic lipids have been shown capable of mediating gene transfer to respiratory epithelial cells both in vitro [5] [6] [7] and into the lungs of small animals. These in vivo studies were conducted by administrating the DNA/lipid complexes via aerosol, intranasal or intratracheal injections into airways of normal and uninjured lungs. [8] [9] [10] [11] Systemic delivery by intravenous injection has also been shown to be effective in transfecting lung tissue. [12] [13] [14] [15] [16] [17] [18] Polycationic polymers, like polyethylenimine (PEI), are a new class of nonviral vectors capable of transfecting in vitro and in vivo a variety of cell types, including respiratory cells. [19] [20] [21] [22] [23] Previous intravenous studies have not directly compared cationic lipids and polymers in transfecting animal model airways.
We undertook the present study to extend our understanding of the feasibility of transfecting airway lung cells by systemic delivery of DNA/lipid complexes (lipoplexes) and to compare their efficiency with that of DNA/polymer complexes (polyplexes). Our data show that the cationic polymer PEI 22K is the optimal vector with this route of administration and that it can transfect lung alveolar cells following a single intravenous administration. We envisioned also a double injection protocol aimed to increase gene transfer levels in vivo and to give an insight into the mechanism of action of nonviral vectors.
Results

In vitro optimization of cationic vectors
To test and compare the relative efficiencies of various cationic lipids and cationic polymers in transfecting air- way-derived cell lines, we evaluated expression of the reporter gene firefly luciferase. In A549, type II pneumocyte-derived epithelial cells, the cationic lipids DOTAP and GL-67/DOPE exhibited higher transfection efficiencies than the cationic lipids DOGS and DOTMA/DOPE but approximately the same efficiency as observed with the polymeric DNA-binding cations PEI 22K and 25K (Figure 1) . In other airway cell lines tested, for example, the human fetal tracheal 56FHT80-and the human CF nasal epithelial cells CFNPE90-, PEI 22K mediated higher luciferase levels than all the other vectors ( Figure 1) . Evaluation of E. coli ␤-galactosidase expression in A549 cell line confirmed that DOTAP, GL-67/DOPE, PEI 25K and PEI 22K showed a higher efficiency of transfection than DOGS and DOTMA/DOPE (Table 1) . It has been previously shown that transfection activity is significantly decreased by the addition of serum to the incubation medium. 24 The effect of serum on gene transfer into A549 cells mediated by DOTAP, GL-67/DOPE, PEI 25K or PEI 22K was tested. We found that the efficiency of gene transfer mediated either by PEI 22K, PEI 25K or DOTAP was not appreciably affected by the presence of serum (Figure 2a, b and c) . In serum-free conditions, luciferase activity mediated by GL-67/DOPE was lower than in the presence of serum at all the N/P equivalents tested (Figure 2d ). The resistance of these cationic vectors to serum suggests that all four vectors could be useful for systemic gene delivery. Figure 2 also shows that optimization of the charge ratio is an important parameter for transfection of airway epithelial cells. For all four vectors, the complexes that gave the maximal luciferase expression were slightly positive (ie 7 N/P equivalents for PEI 22K and PEI 25K, corresponding to 1.2 +/− charge ratio of the complexes; 2.4 N/P equivalents for DOTAP, corresponding to 2.4 +/− charge ratio; 0.5 N/P equivalents for GL-67/DOPE, corresponding to 1.5 +/− charge ratio).
To evaluate the integrity of plasmid DNA in the presence of cationic lipids, its protection from DNase digestion was evaluated. Free DNA presented three forms (relaxed, linear and supercoiled) and was completely degraded when incubated in the presence of DNase I (Figure 3a) . DOTAP partially protected DNA from degradation, whereas, using DOGS as a carrier, no DNA forms were observed. DOTAP was equally effective in protecting DNA at all the lipid/DNA N/P equivalents tested (Figure 3b ). GL-67/DOPE also protected DNA from degradation at the 0.5-1 N/P equivalents but less at the 0.25 N/P equivalent (Figure 3c ).
Relative efficiency of cationic vectors in mediating gene transfer in vivo
We next compared the luciferase levels obtained in various organs of C57Bl/6 mice after intravenous injection of pCLuc DNA complexed to cationic vectors. The peak levels of luciferase expression were found between 24 and 48 h after injection with the complexes (data not shown). Using PEI 22K, the highest levels of luciferase expression were found in the lungs, followed by the other organs, including spleen, liver, kidney and heart (Figure 4a ). Among the other vectors, only DOTAP could determine significant luciferase levels into the lungs, with low levels obtained in this organ with GL-67/DOPE and PEI 25K. Both DOTMA/DOPE and DOGS (not shown) gave negligible expression in all the organs. Injected free plasmid DNA did not gain any gene reporter expression ( Figure 4a ).
As for in vitro studies, the optimal ratio of the vectors to DNA was also evaluated in vivo. Figure 4b shows that the higher the amount of the cationic vector in the complexes the higher the luciferase levels obtained in the lungs. PEI 22K and PEI 25K were most effective when 10-15 N/P equivalents were used, while DOTAP and GL-67/DOPE gave the highest luciferase expression at the 3.6-4.8 and 2-4 N/P equivalents, respectively. Even though the transfection mediated by PEI 25K, DOTAP or GL-67/DOPE increased when more cationic vector in the complexes was used, luciferase levels were approximately from one to four logs below those obtained by PEI 22K. The transfection mediated by PEI 22K or 
to 4.8 N/P equivalents for DOTAP (c), and from 0.12 to 1 N/P equivalent for GL-67/DOPE (d). Evaluation of luciferase levels was carried out after 24 h from the addition of complexes.
DOTAP was dependent on the N/P equivalents also in all the other organs tested (Figure 4c and d). Higher N/P equivalents than those showed determined animal mortality and they were not considered further.
Double injections of cationic vector/DNA complexes
In an attempt to further increase the levels of transfection in the lungs, we administered a second dose of complexes 16 h after the first one, but saw no increase in transfection activity (not shown). The same experiment was performed with shorter intervals between the two injections. When the injections were done with an interval of only 15 min with the pCLuc DNA complexed to DOTAP (at 2.4 N/P equivalents), the luciferase levels increased two logs compared with that obtained using a single injection (Figure 5a) . Surprisingly, similar high levels of expression were obtained when the first dose was comprised of an irrelevant plasmid (pCMV␤n). However, when we inverted the order of the injections (first the pCLuc and secondly the pCMV␤n), the luciferase levels did not increase ( Figure 5a ). Indeed, the single injection of pCMV␤n/DOTAP complexes resulted in background levels. Two injections of PEI 22K/pCLuc (7.5 N/P equivalents) at a 15-min interval resulted in one log increase of luciferase levels ( Figure 5b ). Differently than to DOTAP, injection of polyplexes containing pCLuc either before or after the irrelevant PEI 22K/pCMV␤n complexes did not yield any significant difference with respect to a single injection (Figure 5b ), suggesting a different mechanism of transfection in vivo between cationic lipids and polymers.
Localization of cationic lipid-transfected cells into the lungs
At 24 h following intravenous injection of a plasmid encoding ␤-galactosidase complexed to PEI 22K at 15 or DOTAP at 4.8 N/P equivalents, we evaluated the presence of transfected cells by X-gal staining of whole lungs. Since the pCMV␤n expression vector contains a nuclear localization signal, expression of ␤-galactosidase was observed in cell nuclei of cells lining the alveoli for both PEI 22K and DOTAP (Figure 6a and b) . The higher cell number in PEI 22K-transfected lungs confirmed the luciferase data. Staining of bronchi and bronchioli was not observed. The same pattern of staining was obtained when GL-67/DOPE was used as vector and with double injection protocols using PEI 22K or DOTAP (data not shown). No stained nuclei were found in the lungs of mice transfected with an irrelevant plasmid complex either with PEI 22K or DOTAP. In the attempt to characterize the cellular type target of the cationic polymers and lipids, immunohistochemistry on cryosections with an antibody directed against surfactant protein A (SP-A) was performed. Some of the transfected cells were positive for SP-A expression (Figure 6c, d and e), indicating that these cells were type II pneumocytes. When we used an anti-CD11b antibody to detect macrophages, no colocalization was found with nuclear ␤-galactosidase positive cells (Figure 6f, g and h) .
.8 for DOTAP and 2 for GL-67/DOPE. After 24 h, mice were killed, organs were homogenated with lysis buffer (see Materials and methods), and luciferase expression was evaluated. (b) Intravenous injections were performed with different N/P equivalents of the complexes as indicated and luciferase expression was revealed only in the lungs. In (c) and (d) is shown the optimization of gene transfer to the mice organs using different N/P equivalents for PEI 22K (c) or DOTAP (d). Each experiment was performed with three-seven animals.
Figure 5 Expression of luciferase after two injections of PEI
Discussion
In this study, we compared the relative ability of two different classes of DNA delivering agents, cationic lipids and polycationic polymers, in transfecting lung tissue following a single intravenous injection. Although the cationic vectors tested were able to mediate gene delivery to airway-derived cell lines in vitro with high efficiency, only some of them showed significant activity in vivo (PEI 22K Ͼ DOTAP Ͼ GL-67/DOPE Ͼ PEI 25K).
Our data indicate that the behaviour of any vector tested previously in vitro is only partially reproducible in vivo for an intravenous administration. Indeed, optimization of the overall charge of the complexes revealed significant differences between in vitro and the in vivo system. The more positive the complexes injected in the tail vein the more luciferase levels were obtained in the lungs, whereas less positive complexes were optimal in vitro. These data are in agreement with other studies in which a larger excess of positive charges are required for lung transfection through intravenous administration. 25 On the other hand, neutral polyplexes were shown to be optimal in transfecting the lungs through the intratracheal route (Ref. 22 and our data not shown) and DNA/PEI complexes bearing ionic charge ratios closest to neutrality gave the highest levels of transgene expression in the mature mouse brain. 26 This difference between intravenous and the other routes of administration might be due to the presence of serum components in the first case. Although the presence of serum in the transfection medium has been demonstrated to inhibit gene transfer activity of cationic lipids, 24 our data show that both lipoplexes and polyplexes are resistant to serum inhibition (Figure 2 ). DOTAP and GL-67/DOPE could protect the plasmid DNA from DNase degradation, a property not shared by DOGS (Figure 3 ). These properties could explain in part the cationic vector efficiency in lung transfection after a single intravenous injection. PEI transfection was shown to be resistant to serum but, because it was not possible to separate DNA from PEI with a simple organic phase extraction, due to its chemical nature, DNA protection assay could not be performed with these polyplexes.
We obtained the higher levels of lung transfection (3 × 10 7 RLU/mg protein) using a linear 22K form of PEI than those achieved with branched counterpart PEI 25K. Previous studies using scanning force microscopy have shown that the vast majority of complexes were 20-40 nm in diameter for both the linear PEI 22K and branched PEI 25K, although a small number of much larger complexes resulted from condensation of DNA with PEI 25K. 27 This difference in size distribution might be important when polyplexes have to interact with the endothelial luminal membrane. Small size of the complexes has been considered a critical parameter for in vivo delivery to cross barriers such as endothelial cell fenestrations and dif-
Figure 6 Identification of transfected lung cells in vivo following systemic administration of PEI 22K and DOTAP/DNA complexes. C57Bl/6 mice were injected into the tail vein with 50 g of pCMV␤n complexed to PEI 22K at 15 N/P equivalents (a, c, d, f and g) or DOTAP at 4.8 N/P equivalents (b, e and h) and nuclear ␤-galactosidase expression was evaluated by X-gal staining (see Materials and methods) after 24 h. (a) and (b) Microphotographs showing that the transfected cells are localized in the alveolar regions. Original magnification 20×. (c), (d) and (e) Co-localization of the nuclear ␤-galactosidase staining (blue) with the detection of SP-A (brown) in a single alveolar cell. Original magnification 100×. Inset in (e) depicts an enlargement of the cell showing both SP-A and ␤-galactosidase expression. (f), (g) and (h) Absence of co-localization between ␤-galactosidase-positive cells and staining for CD11b (identifying macrophages). Original magnification 100×.
fusion into the tissues. It has been shown that the ionic strength of the solution in which polyplexes are formed influences their size. In fact, small polyplexes (40 nm) were obtained at low ionic strength (5% glucose), while large complexes (up to Ͼ1000 nm) were formed in physiological salt concentrations. 28 Moreover, Goula et al 29 showed that increasing the N/P ratio of the polyplexes decreased the size of particles formulated in glucose, whereas this effect was not observed when the complexes were formed in NaCl. Preliminary experiments using a physiological salt concentration for the intravenous administrations of complexes resulted in approximately 1000-fold less transgene levels in the lungs than using complexes formed in 5% glucose (data not shown), demonstrating that the small complexes are more efficient in vivo for the intravenous injections than the large complexes. To increase the activity of polyplexes in vivo, we tried different protocols, but we found no improvement in lung transfection with either increasing amounts of DNA or by pre-condensing DNA to poly-l-lysine (not shown).
Others have found that using linear PEI 22K at 4 equivalents and 125 g DNA, it was possible to obtain high levels of lung transfection (1 × 10 7 RLU/mg protein). 23 We achieved these same levels using PEI 22K at 15 equivalents with 50 g DNA (Figure 4 ). Since it has been shown that bacterial DNA can induce acute inflammation in the lower respiratory tract after intratracheal instillation, 30 our experimental conditions should favor less toxicity of polyplexes. Infact, when Goula et al 23 used 125 g DNA with a N/P ratio of 6, those polyplexes were toxic in 50% of the mice injected, while when we used the same amount of the cationic polymer with 50 g DNA at N/P of 15, no toxicity was observed. This could also be the reason why a high toxicity with PEI 25K was shown even at low N/P ratios, making impossible for these authors a direct comparison between the two forms of PEI. 23 On the other hand, it has been shown that PEI 25K can activate the complement. 31 DOTAP was the most efficient vector in vivo among the cationic lipids, but nevertheless, it did not reach the levels obtained with PEI 22K. Besides the different chemical configuration, the lower activity of DOTAP might be ascribed to the size of the particles which were shown to be between 180 and 280 nm. 32 DOTAP and GL-67/DOPE are composed of a hydrophobic lipid anchor group capable of interacting with membranes, linked to a positively charged headgroup that binds to and condenses the DNA. GL-67 is a new cationic lipid that arose from structure-function studies and was shown to be more efficient than other cationic lipid preparations when given intranasally. 33 Therefore, it was surprising to observe that DOTAP was more efficient than GL-67/DOPE after a single intravenous injection. Clearly, factors other than chemical configuration must be important when the systemic route is used. Another two cationic lipids (DOGS and DOTMA/DOPE) were not efficient in mediating gene transfer either in vitro or in vivo. One possible explanation comes from the finding that DOGS can strongly activate complement. 31 In the same study, DOTAP and DOTMA/DOPE were also shown to be weak activators of complement. Again, the different efficiency of DOTAP and DOTMA/DOPE must be found in other properties.
Repeated doses of DOTAP complexes (50 g given twice in a 16-h interval) did not increase luciferase expression in the lung (not shown). In contrast, a similar experiment carried out with a short time interval between the two doses (15 min) determined luciferase levels that were greater than two logs over those obtained with a single administration. Since the double injection of DOTAP/DNA complexes with 4.8 N/P equivalents was toxic, it was possible to perform this protocol only with 2.4 N/P equivalents. Interestingly, the large increase in luciferase activity was obtained with either DOTAP/pCMV␤n or DOTAP/pCLuc complexes used as the first dose. These results are similar to those obtained by pre-injecting cationic lipids and subsequently either naked DNA 34 or DNA/lipid complexes. 35 A possible explanation is that aggregates between DNA complexes and serum proteins are trapped in lung capillaries and thereby retain the DNA complexes injected later. It might also be possible that the first injection saturates the macrophage cells, 36 allowing the second injection to overcome the cellular barriers to intravenous administration. An increase of luciferase levels was reached with the double injection of PEI 22K/pCLuc complexes in a 15-min interval with respect to a single injection, but a clear difference using an irrelevant plasmid as first dose was not observed. Since this is the first time to our knowledge that double injection protocols have been exploited with polyplexes for an intravenous route, further studies are needed to comprehend the mechanism underlying PEI 22K lung transfection in vivo.
In previous studies performed using the systemic route, recombinant protein was localized either in the alveolar region 12, 18 or in the endothelium of microvessels present in the alveolar septi. 16, 17, 25 Recently, DNA was shown in type II alveolar epithelial cells, 18 a finding confirmed by our protein data. Indeed, we have found transgene expression only in cells lining the alveoli. Cytochemical characterization indicates that some of those cells are type II pneumocytes. Since alveolar macrophages never stained positive for ␤-gal expression, these results could be due to the lack either of macrophage transfection or of transgene expression by these cells.
Alveolar type II cells are potential targets for the gene therapeutic treatment of congenital lung diseases such as neonatal respiratory distress syndrome and congenital pulmonary alveolar proteinosis, or ␣ 1 -antitrypsin deficiency and cystic fibrosis. In the case of CF, it is still not known which cell type is responsible for the pathogenesis of the disease. However, it has been shown that CFTR is expressed in alveolar type II precursors and in differentiated type II pneumocytes. 37 It would be interesting to see if CFTR transfection in CF-type II pneumocytes in vivo resulted in any change of CF phenotype.
Materials and methods
Cell lines A549 (human type II pneumocytes), 56FHT80-(human fetal tracheal epithelium) and CFNPE90-(a CF nasal epithelium) cells were grown in DMEM/HAM F12 (1:1) containing 10% fetal calf serum (FCS), 2 mm l-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. A549 cell line was from American Type Culture Collection (ATCC, Rockville, MD, USA). 56FHT80-and CFNPE90-cell lines were a kind gift of Dr D Gruenert (University of California, San Francisco, CA, USA). Each cell line was maintained in culture until the 10th-12th passage.
Plasmids
Plasmids pCLuc, carrying the P. pyralis luciferase coding region under the control of the cytomegalovirus (CMV) immediate-early enhancer/promoter region, and pCMV␤n, coding for a nuclear form of E. coli lacZ gene driven by the same promoter were kind gifts of Dr L Monaco (HS Raffaele, Milano, Italy). Plasmid carrying the cytosolic form of lacZ gene (pCMV␤) was purchased from Clontech Laboratories (Palo Alto, CA, USA). Plasmid DNA preparation was performed by double CsCl gradient purification. 38 A 260 /A 280 was determined spectrophotometrically and was between 1.8 and 2.0. Purity of the plasmids was also checked by 1% agarose gel electrophoresis.
Cationic vectors-DNA complexes formation Linear 22-kDa polyethylenimine (PEI 22K) (Exgen 500; Euromedex, Souffelweyersheim, France) was purchased as 5.47 mm (0.4 mg/ml) aqueous stock solution. Branched 25-kDa PEI (PEI 25K) (Sigma-Aldrich, St Louis, MO, USA) was used as 100 mm (4.5 g/l) aqueous stock solution. DOTAP (Boehringer Mannheim, Mannheim, Germany) was purchased as a 1 mg/ml aqueous solution. DOGS (Transfectam) was a kind gift of Dr J-P Behr (Strasbourg, France) and was used as a 2 mm ethanolic solution. DOTMA/DOPE (Lipofectin; Gibco BRL, Life Technologies, Gaithersburg, MD, USA) was obtained as a 1 mg/ml aqueous solution. GL-67 was formulated with DOPE at a molar ratio of 1:2 33 and was reconstituted as 1 mm aqueous solution. For complex formation, the following amounts of each vector were used per 2 g of DNA: from 2.5 to 15 equivalents of PEI nitrogen per DNA phosphate, that is from 0.15 to 0.6 l of PEI 25K solution 19 and from 2.7 to 16.4 l of PEI 22K solution; for DOTAP, from 1.2 to 4.8 equivalents of DOTAP per DNA phosphate, corresponding from one-to 12-fold weight excess, that is from 6 to 24 l of DOTAP solution; 6 equivalents of DOGS protonated nitrogen per DNA phosphate, that is 6 l of DOGS solution; 
In vitro transfections
Cells were seeded on to 24-well plates at 40 000 per well to obtain 60-70% confluency after an overnight incubation. Complexes prepared with 2 g of DNA in 100 l of transfection solution were added to each well. All the experiments with PEI 22K, PEI 25K, DOTAP and GL-67/DOPE were performed in the presence of serum, except where indicated. FCS (10%) was added to the transfection medium after 3-6 h incubation of DOGS or DOTMA/DOPE complexes with the cells. The plates were centrifuged for 10 min at 410 g. Cells were incubated with the complexes for 24 h and then evaluated for transgene expression.
Assay for luciferase activity in vitro Twenty-four hours after transfection, cells were rinsed twice in PBS and then lysed with 100 l of cell lysis buffer (25 mm Tris/HCl, 2 mm DTT, 2 mm EDTA, 10% glycerol, 1% Triton X-100, pH 8.0). Twenty microliters of cell lysate were mixed with 70 l of luciferase assay substrate (Promega, Madison, WI, USA) at room temperature and the light emission (integrated over 30 s) was quantified with an LB 9501 luminometer (Berthold, Bad Willbad, Germany). Relative light units (RLU) were normalized to the protein content of each sample, determined according to Bradford's assay for protein concentration (Bio-RAD, Mü nchen, Germany).
Cytochemical assay for ␤-galactosidase activity in vitro Individual cells expressing ␤-galactosidase were identified after incubation with 5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside (X-gal). Briefly, the cells were fixed with a solution of 0.2% glutaraldehyde, 2% formaldehyde in PBS for 15 min at 4°C, washed twice with PBS, pH 7.5, and then incubated with a solution containing 1 mg/ml X-gal dissolved in 5 mm potassium ferricyanate, 5 mm potassium ferricyanide, and 2 mm magnesium chloride in PBS (pH 7.4) for 6-8 h at 37°C.
DNase protection assay pCLuc (576 ng) complexed to the cationic vector was incubated in a buffer containing 20 mm magnesium chloride in the presence or absence of 10 U of DNase I (Boehringer Mannheim). The reaction was carried out for 3 h at 37°C. DNA was isolated by using the phenolchloroform extraction and its integrity was examined by fractionation through a 1% agarose gel and ethidium bromide staining. Free DNA was used as a control.
Injection of DNA complexes into the tail vein Complexes were formed by adding 500 l of transfecting reagent in 5% w/v glucose (at the appropariate ratio to DNA as described above) into 100 l of DNA solution in glucose. For the highest DNA/DOTAP (4.8) and GL-67/DOPE (4) N/P equivalents 600 l of transfecting reagent were used. C57Bl/6 mice of 4-6 weeks of age were used. Individual mice in groups of three were injected intravenously with 50 g of DNA complexed with the vector in a total volume of 600-700 l. Twentyfour hours after i.v. injection, mice were killed and organs were removed and assayed for gene expression.
Assay for luciferase activity in vivo After reperfusion with 10 ml 150 mm NaCl, lung, heart, spleen, liver and kidney were collected and washed with cold saline. The organs were homogenized on ice in 2 ml of lysis buffer as described above. The homogenates were centrifuged at 15 800 g for 10 min at 4°C, and 70 l of the supernatant was analyzed for luciferase activity using a single-well luminometer for 30 s. Luciferase activity was measured employing a luciferase assay kit (Promega). In parallel, purified luciferase (Boehringer Mannheim) dissolved in the supernatant of homogenates from the different organs of nontreated animals was used as a standard. In these conditions, a conversion factor of 15160 RLU/pg luciferase was obtained for the lungs, 3106 RLU/pg for the liver, 7976 RLU/pg for the kidney, 10456 for the spleen, and 7058 for the heart.
In situ ␤-gal assay on lung cryosections The lungs were reperfused through the heart with 10 ml of normal saline solution. Lungs were removed by dissection, rinsed in normal saline solution and fixed for 60 min at room temperature in 4% paraformaldehyde. The staining was performed in potassium phosphate buffer 100 mm (pH 7.4), 5 mm EGTA, 2 mm magnesium chloride, 0.01% Na deoxycholate, 0.02% Nonidet P-40, 0.5 mg/ml X-gal, 10 mm potassium ferricyanate, and 10 mm potassium ferricyanide overnight at 37°C. The organs were cryoprotected in 10% sucrose and subsequently frozen samples were included in OCT (Miles, Elkhart, IN, USA), cryosectioned into 8-m sections with a cryostate, and mounted on glass slides. Slides were subsequently washed in normal saline solution, counterstained with Harris Hematoxylin (Sigma), and coverslipped with aqueous mounting media (Electron Microscopy Science, Washington, PA, USA). Blue cells were detected by direct light microscopy.
Immunohistochemical stainings
The rabbit polyclonal antibody raised against human surfactant protein A (SP-A) was kindly provided by Dr J Alcorn (Southwestern Medical Center, Dallas, TX, USA) and identifies type II penumocytes. 40 The rat IgG2b monoclonal antibody M1/70, a kind gift of Dr I Simon, Harvard Medical School, Boston, MA, USA, was raised against the unique ␣ subunit of mouse Mac-1 (CD11b) 41 and identifies tissue macrophages. Immunohistochemistry was carried out using the avidin-biotin-peroxidase detection system (ABC Vectastain Elite kit; Vector Laboratories, Burlingame, CA, USA). Briefly, incubation of cryosections with the appropriate dilution of the primary antibody (anti-SPA, 1:25; anti-CD11b, 1:50) was carried out for 1 h at room temperature in PBS, 1% BSA, 2% normal goat serum. After washing in PBS, sections were incubated with biotinylated secondary antibody (antirabbit IgG H+L and anti-rat IgG H+L from Vector Laboratories) for 1 h at room temperature. Detection was carried out by a chromogenic reaction using 3-amino-9-ethyl-carbazole (Sigma) as substrate, according to the manufacturer's instructions. Slides were counterstained with Harris Haematoxylin and mounted with aqueous mounting media.
